These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 6767311)
1. [Surgical method and combination chemotherapy in treating stage-III and IV ovarian cancer]. Grigorova TM; Vartanian LG; Marenich AF Vopr Onkol; 1980; 26(2):81-5. PubMed ID: 6767311 [TBL] [Abstract][Full Text] [Related]
2. Treatment of advanced ovarian carcinoma with a combination of hexmethylmelamine, cyclophosphamide, methotrexate, and 5-fluorourcil (hexa-CAF) in patients with and without previous treatment. Neijt JP; van Lindert AC; Vendrik CP; Roozendaal KJ; Struyvenberg A; Pinedo HM Cancer Treat Rep; 1980; 64(2-3):323-6. PubMed ID: 6773656 [TBL] [Abstract][Full Text] [Related]
3. [Comparative study of 2 combined treatment regimens in stage-III to -IV ovarian cancer]. Evdokimova NI; Grigorova TM Vopr Onkol; 1982; 28(7):28-34. PubMed ID: 7101824 [TBL] [Abstract][Full Text] [Related]
4. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878. Wadler S; Yeap B; Vogl S; Carbone P Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766 [TBL] [Abstract][Full Text] [Related]
6. Hexamethylmelamine-CAF (cyclophosphamide, methotrexate, and 5-FU) and cisplatin-CAF in refractory ovarian cancer. Sessa C; D'Incalci M; Valente I; Bolis G; Colombo N; Mangioni C Cancer Treat Rep; 1982 May; 66(5):1233-4. PubMed ID: 6805951 [No Abstract] [Full Text] [Related]
7. Combination v. sequential therapy with melphalan, 5-fluorouracil and methotrexate for advanced ovarian cancer. Miller AB; Klaassen DJ; Boyes DA; Dodds DJ; Gerulath A; Kirk ME; Levitt M; Pearson JG; Wall C Can Med Assoc J; 1980 Sep; 123(5):365-71. PubMed ID: 7020903 [TBL] [Abstract][Full Text] [Related]
8. Improved therapy with cisplatin regimens for patients with ovarian carcinoma (FIGO III and IV) as measured by surgical end-staging (second-look surgery)--the mount sinai experience. Cohen CJ; Bruckner HW; Goldberg JD; Holland JF Clin Obstet Gynaecol; 1983 Aug; 10(2):307-24. PubMed ID: 6413114 [No Abstract] [Full Text] [Related]